[18], in their randomised controlled trial, strengthened these findings by illustrating the profound effect of GLP‐1 RAs in reducing biomarkers of nonalcoholic steatohepatitis. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.